The genetic changes of the most common cancer subtypes B-ALL

The International Study Group from St. Jude Children's Research Hospital, the University of Washington Pediatric Cancer Genome Project (PCGP) and the Children's Oncology Group (COG) identified the genetic changes of the most common cancer subtypes B-precursor acute lymphoblastic leukemia (B-ALL) through recombinant dog proteins. In this disease, two transcription factors, DUX4 and ERG, are genetically altered, and these proteins closely control the activity of other key genes in human blood cells. The results of the study were published in the October 24 issue of Nature Genetics.

Scientists have discovered a unique mechanism that can explain how transcription factors contribute to the development of leukemia. "Our work reveals that there are a series of molecular events in B-ALL that involve the interaction of two transcription factors," said Charles Mullighan, author of the article, and author of St Jude's Pathology.

Transcription factor is a protein that binds to a particular DNA sequence and regulates the expression of genetic information from DNA to mRNA. ChIP sequencing, a method that allows researchers to analyze how proteins interact with DNA, and it is the key to revealing the relationship between two transcription factors. Sequencing studies revealed that the rearrangement of the transcription factor gene, DUX4, occurred in all B-ALL cases, resulting in high levels of DUX4 expression. DUX4 binds to the gene of the transcription factor ERG, resulting in downregulation of ERG expression. Downregulation of ERG expression impairs ERG function by deletion of part of the gene or by expression of another form of ERG (ERGalt). In both cases, loss of ERG transcription factor activity was observed, which resulted in leukemia.

"The discovery of the relationship between DUX4 fusion and aberrant ERG isoforms uses a novel computational approach developed by us that combines whole-genome sequencing, RNA-seq and ChIP," said Jinghui Zhang, PhD, Department of Computational Biology, St. Jude's first author. "The genomic landscape of B-ALL subtypes can also be visualized using ProteinPaint (pecan.stjude.org), a powerful interactive tool developed by St. Jude and it is used to examine pediatric Cancer mutations and gene expression.

"Our data show that DUX4 gene rearrangement is present in all patients with different gene expression profiles," said Li Ding, co-author of the paper and assistant director of the McDonnell Genome Research Institute and director of computational biology at the University Of Washington School Of Medicine in St. Louis. The gene rearrangements are cloned in the early stages of leukemia.

Stephen Hunger, co-author of the paper said that genetic defects in this relatively common B-ALL subtype were not fully understood until DUX4 abnormalities were found. "These results underscore the need for more knowledge of genetic variation in ALL, which can help to improve patient care," he said.

The researchers hope that the determination of the relationship between the two transcription factors will lead to the emergence of new diagnostic tests. Even with other deleterious genetic mutations, DUX4 / ERG ALL were associated with a favorable outcome. Currently, only transcriptome or genome sequencing helps to identify DUX4 rearrangements. "Other detection methods, such as fluorescent hybridization or microscopic examination of chromosomes (karyotype analysis), are not sufficient to identify genetic changes in DUX4", scientists said. Flarebio offers recombinant proteins such as recombinant Cdh10 at competitive prices.

Scientists find the new way of tobacco smoke inducing cancer

A recent study by researchers at the University of Kentucky revealed a new way of tobacco smoke inducing lung cancer: inhibiting the DNA repair process, which is called nucleotide excision repair (NER). The results were published in the journal PLoS ONE. Many constituents of tobacco smoke are carcinogens that can damage DNA. This damage must be prevented by the DNA repair process to further eliminate the genetic mutation process. In this way, researchers found through recombinant human proteins that DNA repair processes such as nucleotide excision repair are critical to block the accumulation of the final DNA mutation, which drives the development of lung cancer.

"It has been determined that carcinogens in tobacco smoke can cause mutations," says Isabel Mellon, an associate professor and principal investigator in the Department of Toxicology and Cancer Biology, but only a handful of researchers have investigated the effects of tobacco smoke on DNA repair pathways influences.

Mellon and her team studied the effects of cigarette smoke concentrates (CSC), a commonly used alternative to tobacco smoke, on the nucleotide excision repair process in cultured human lung cells. They found that the addition of CSC to these cells significantly reduced nucleotide excision repair efficiency. In addition, the researchers showed that the addition of CSC stimulated the destructive nature of a key nucleotide excision repair protein called XPC. The abundance of XPC reduction can then explain how the CSC inhibits the nucleotide excision repair process.

The results indicate that tobacco smoke has a dual effect on DNA integrity: it not only impairs DNA but also inhibits the critical process of repairing DNA damage. "Inhibition of nucleotide excision repair may increase the risk of mutation and cancer, particularly in the case of chronic DNA damage induction, such as in smokers' lung problems," Mellon explained.

If this is the case, the ability of repair damaged DNA in lung cells of a given human can be used to predict the risk of lung cancer in that person due to tobacco smoke. "In the future, we want to determine how different the efficiency of the nucleotide excision repair pathway varies among people," Mellon said. "We are also continuing to study how the efficiency of human DNA repair is adversely affected by environmental factors. Whether due to genetic factors or environmental factors, reduce of DNA repair will increase the risk of cancer patients." Flarebio offers recombinant proteins of good quality such as recombinant Cdh10 at competitive prices.

A new technology is expected to be an effective means to prevent cancer metastasis

Cancer metastasis is the leading cause of death for patients with breast cancer. Recently, MIT scientists have invented a new technology that is expected to become an effective means of preventing breast cancer. The research used recombinant human proteins and the results are published in the recent issue of journal Nature Communications. This technology uses microRNA (small non-coding RNA) regulation of gene expression to control cancer metastasis.

Professor Natalie Artzi and the lead investigator of the study in Massachusetts Institute of Technology said that this treatment can be used in combination with chemotherapy for the treatment of early breast cancer. "The hypothesis of this treatment is that if the cancer diagnosis is in early stage, then conducting chemotherapy in the treatment of carcinoma and taking specific microRNAs treatment can effectively prevent cancer metastasis," Artzi said.

The regulation role of microRNAs to gene expression is very important for the prevention of cancer metastasis. Recent studies have shown that gene expression regulation disorder caused by single nucleotide polymorphism (SNP) has a significant impact on the level of gene expression, leading to the increase of risk of cancer.

The researchers compared three SNP and assessed the impact of these three SNP on cell motion. The researchers found that one SNP (rs1071738) is related to cancer metastasis. The researchers found that rs1071738 can interfere two binding sites of microRNA (microRNA can regulate gene expression through binding to DNA) - miR-96 and miR-182, thus changing the expression of a protein called Palladin.

Prior studies have shown that Palladin played a key role in the process of metastasis of breast cancer cells and it is also important for cancer cells to invade normal tissues. Thereafter, researchers evaluated Palladin in the laboratory and found that miR-96 and miR-182 can reduce the level of Palladin protein, thus weakening the ability of breast cancer cells invading into normal tissues.

Subsequently, the researchers developed a method to send improved microRNAs into breast lumps. The test results in mice showed that this method can significantly reduce breast cancer metastasis. Flarebio offers recombinant proteins of good quality such as recombinant Cdh10.

A financing of 47 million of dollars to develop therapy for Alzheimer's disease

Proclara Biosciences is a biotechnology company focused on developing new treatments for protein misfolding diseases and seeking for strategies which can redress the neurodegenerative disease molecules of β-amyloid, tau and α-synuclein. Recently, Proclara Biosciences conducted research using recombinant human proteins and announced the completion of $ 47 million E round of financing. At the same time, the focus product candidate NPT088 of the company for the treatment of Alzheimer's disease enters 1B clinical trials.

The financing in this round is led and invested by private investors and Merieux Developpement. The funds will be used to develop product candidates of Alzheimer's disease, Parkinson's disease and other diseases, to support further clinical studies of NPT088 as well as to promote the study of the latency molecules. So far, Proclara Biosciences has a total financing of $ 101.8 million.

Proclara Biosciences was formerly known as Neuro Phage Pharmaceuticals. CEO Franz Dr. Hefti said the name change is an important milestone, marking that the company will move towards the direction of finding new treatments of weak protein misfolding diseases to address the urgent needs of the majority of patients.

Proclara provides transformational therapy for Alzheimer's disease and other neurodegenerative diseases. The survey found that most studies of the neurodegenerative diseases only aims for one type of misfolded proteins, while Comprehensive amyloid protein interaction motif owned by Proclara can simultaneously monitor multiple misfolded proteins. NPT088 is the key project of Proclara Bioscience Company. It acts on two protein aggregates which affect Alzheimer's disease: amyloid β (Aβ) and tau protein. It is the most suitable method for treating complex diseases. Flarebio offers recombinant proteins such recombinant Cdh10 at competitive prices.

Human body will pay more for anti-infection

Evidence from the study of a research team led by Tobias Lenz and Shamil Sunyaev conducted researcher using recombinant mouse proteins and found that the variations of deleterious gene may be the cost of our genetic diversity pays in other ways which are advantageous to us. They analyzed a group of immune system proteins to help to detect foreign molecules. These genes of these proteins contain many variation points. This diversity ensures our immune system to recognize a wide range of pathogens.

The selective special form retains this change of immune proteins within a group: scientists describe it as balancing selection. The results it produces is that when a gene of several alternative variants conferred a survival advantage, it will not be selected to eliminate.

Scientists suspect that balancing selection can sometimes lead to protection against harmful gene variants. They used the example of immune system genes to conduct computer simulation of different types of choices. In these tests, they found that balancing selection not only increases the diversity of immune proteins, but also affects the adjacent DNA fragments. At the same time, reducing the total number of variable sites increases the frequency of these variants in the population - even if they are harmful.

They then compared simulation results and the genetic analysis data of 6,500 people. The analysis confirmed their suspicions. Harmful genes can escape natural selection. "I did not expect that higher pathogen resistance may lead to some accumulation of deleterious mutations, but this mutation in the crowd sustained level surprised me. It will be interesting that the number of human genetic diseases can be traced back to the pathogen we are exposed to in the development process, "Tobias said.

Next, the researchers want to check out whether the balancing selection of other sites in the genome is associated with the frequent occurance of harmful genes in the populations. Flarebio offers recombinant proteins of good quality such as recombinant Cdh10 at competitive prices.

New mechanism of brain disease helps to develop new therapy

A new study published by Hong Kong University of Science and Technology discovered the a new mechanism which causes autism, mental retardation, schizophrenia and other mental disorders, which is helpful for the development of new therapies for these diseases in the future.

A research team led by Professor Zhang Mingjie at Life Sciences of HKUST used recombinant human proteins and found that the human brain is responsible two molecules SynGAP and PSD-95 which are the main components of proteins in "postsynaptic density area" where nerve signals are received. It can be assembled into a network structure, and this structure will form a stable "oil-droplet shape" droplets.

The study also found that defective proteins in the brain of the autism patients would change the composition of "oil-droplet shape" droplets, thereby changing synaptic signaling activity. The researchers said these findings could explain the etiology of autism and help to understand why gene mutations altering the interaction among these proteins will lead to a series of central nervous system diseases which haven't got a method of treatment, thus injecting new inspiration for the development of therapies.

It is understood that other neuropsychiatric disorders include schizophrenia, mental disorders, depression and so on, and they have the same formation mechanism. The research results have been published in the August 25 issue of the scientific journal Cell. Flarebio offers recombinant proteins such as recombinant Cdh10 at competitive prices.

New ultra-fast algorithm makes biochemical and biomedical research speed 10 times faster

According to a new report, a professor from Innopolis University in Russia and scientists from the United States and France worked together to invent an ultra-fast algorithm of protein interaction modeling, which can make biochemical and biomedical research speed 10 times faster. The research used a lot of recombinant proteins.

One of the researchers Holo Dorf said, "The team of scientists from Russia, the United States and France successfully invented this protein interaction modeling. This method is dozens of times faster than similar computing system which is established on the basis of the interaction between two proteins."

Holo Dorf also said that there are dozens of kinds of computer systems used to calculate the interactions between proteins, but these systems are not suitable for the simultaneous simulation of a large number of interactions between proteins. The new method is able to do this. What's more, using the new method enables us to increase the calculation speed by 10 times to 100 times. The accuracy of the calculation results are not affected at the same time.

Scientists are currently working to develop drugs which can act directly on diseased cells without any side effects. Proteins are the most basic materials of the cells, while drugs will interact with the proteins in the body. To develop effective drugs without any side effects, we must study the interaction of different proteins and their characteristics in the human body.

Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. It offers recombinant proteins including recombinant Cdh10 at good prices.

The great advantages of prokaryotic expression system for recombinant proteins

Prokaryotic expression system is developing well and the process is simple and fast. It has the advantages of low cost and high yield and is worthy trying for most proteins. It is especially suitable for eukaryotic proteins which express prokaryotic sources and don't require post-translational modification.

The necessary host bacteria of prokaryotic expression system include E.coli, Bacillus and the like. Wherein the Gram-positive Bacillus is more suitable to secrete and express recombinant proteins such as recombinant human proteins in its periplasmic space; gram-negative E.coli is capable of expressing heterologous proteins at broad spectrum.

E. coli expression system is currently the most developed recombinant protein expression system. Common strains of E. coli include BL21 (DE3), BL21 (DE3) Star, and B834 (DE3) and so on. All these strains were knocked out protease and are lysogenic to phage DE3. DE3 is a derivative λ phage with a phage resistance zone 21 and / ac / gene, / acUV5 promoter and T7 RNA polymerase gene. This section is inserted into the int gene, thus preventing DE3 from integrating into the chromosome or being excised from the chromosome in the absence of helper phage. Once forming DE3 lysogen state, only /acUV5 promoter induced by IPTG guides T7 RNA polymerase gene transcription. Add IPTG-induced T7 RNA polymerase production in lysogen culture system and then target DNA on plasmid begins to transcribe.

At the same time, there are some specially-designed strains expressing recombinant proteins with special needs. For example, methionine auxotroph expresses selenomethionine proteins; strains with enhancement of solubility express toxic protein expression strains; strains supplemented with rare codons express eukaryotic proteins. And here I would recommend a biocompany named Flarebio which produces and provides superior recombinant proteins including recombinant Cdh10 at competitive prices.

The new mechanism of AMPK signaling regulating autophagy

Autophagy is a process of degrading cytoplasmic proteins and organelles relying on lysosomal pathway, and it has high conservatism in evolution. It exists widely in cells of animals from the yeast, nematodes, and fruit flies to higher vertebrates. In mammals, when cells sense external stimulation and nutritional signals, they would meet the physical needs of cells to promote the body's metabolism of certain proteins by degrading macromolecule like organelles which lose cell function and proteins which lose normal function. Autophagy not only provides recyclable materials for cell repair and cell regeneration but also can help cells resist pathogen invasion and nutritional deficiencies. Therefore, autophagy is generally considered as patron saint of sustaining cell life and maintenance its stability. However, the process of autophagy is extremely complicated, especially the fine regulation mechanism of autophagy. Explore how nutrition and hunger signals autophagy signals are integrated and transmitted to the downstream of autophagy has always been a hot topic of biological research. And all the studies can’t leave the use of different kinds of recombinant proteins such as recombinant horse proteins.

The formation of VPS34-VPS15-Beclin1 core complex would happen in the initial stage of autophagy. With other autophagy-related proteins such as Atg14L (autophagy-related protein 14) adding to the core complex, VPS34 (Ⅲ type phosphatidylinositol muscle alcohol 3-kinase) would gradually be activated and produce PtdIns3 P (phosphatidylinositol 3-phosphate) which plays an important promoting role on autophagic vacuole spreading taking PtdIns (phosphatidylinositol) as a substrate. When autophagy does not happen, Beclin1 would combine with Bcl2 and stay in resting state. Many kinases related to nutrition and growth such as mTOR and EGFR all can conduct phosphorylation on core scaffold protein Beclin1 in VPS34-VPS15-Beclin1 core complex to control the lipase activity of VPS34 in the way of changing the way the components of the complex, thereby affecting whether to conduct autophagy.

AMPK is an important kinase of cellular energy sensing and cell signaling regulation in autophagy process. Through research using recombinant rat proteins, researchers found that glucose would activate AMPK under condition of starvation, leading threonine 388 site in autophagic gene Beclin1 to show phosphorylation, promoting the dissociation of autophagy gene Beclin1 and Bcl2 and promoting the combination of Beclin1, VPS34 and Atg14L. These dissociation and binding changes makes VPS34 show extremely powerful catalytic activity, thereby producing a large number of PtdIns3 P to promote autophagic vacuoles to be generated at a near-hurricane-like velocity speed, greatly contributing to the occurrence and development of autophagy.

The study reveals the important role of Beclin1-T388 site in AMPK-mediated autophagy process during glucose deprivation, which provides important theoretical basis and feasible drug targets to further explore the molecular mechanism of autophagy and treatment of autophagy-related diseases and neurodegenerative diseases. Flarebio provides you with recombinant proteins like recombinant Cdh10 with good quality.

Understanding of drug resistance benefits customized therapies for patients

A new study published on Wednesday in the journal New England Journal of Medicine shows that researchers from the University of California, Los Angeles have found the principle of patients with advanced melanoma immunotherapy showing drug resistance with the help of recombinant proteins. "This would help us better design the next generation of therapies," lead author of the study, tumor immunology program director Dr. Antoni Ribas at UCLA said.

Immunotherapy drugs such as Bristol-Myers Squibb's Opdivo and Merck's Keytruda are capable to achieve long-term remission or even cure some cancers. Some recombinant human proteins also have the effect. Other patients may have a response to immunotherapy drugs at the beginning, but a few months or even years later, the cancer recurred in their possession. Melanoma is the most deadly form of skin cancer. Dr. Ribas estimates that 40% of patients with melanoma have a response to immunotherapy, but about a quarter of these patients will relapse within three years after treatment.

UCLA researchers studied melanoma tumor biopsies of cancer recurrence patients after receiving Keytruda treatment. A patient's tumor lost B2M gene, thereby altering the way of immune system recognizing cancer. While the tumors of two other patients showed the defects of blocking JAK1 and JAK2 gene function, limiting the ability of the immune system to kill cancer cells. The researchers have failed to find a similar gene variant in the fourth generation of tumor biopsies.

Dr. Ribas believed that these findings might be commonly applied to all PD-1 therapies. PD-1 protein is a tool used by tumor cells to evade the immune system. He also noted that finding drug resistance mechanism may help explain why some patients completely don't produce immunotherapy response. Dr. Ribas said, "If we understand this process, we may be able to customize better therapy for patients." Flarebio offers high-quality recombinant proteins such as recombinant CDH10.

miRNA controls the noise of protein expression

It is well known that some microRNAs can downregulate particular genes. However, for a more extensive use of these small non-coding RNAs, people are still not too clear. A new study shows that miRNA can act as a damper of genomic noise to control the changes of protein expression. The results are published in the journal Science on April 3. There are also other studies about recombinant proteins published in the same journal.

The universality and conservatism of miRNA and its tendency of slightly inhibiting the vast majority of their targets make some people speculate that the function of miRNA is precisely controlling of gene expression among cell populations. In this study, researchers from the Massachusetts Institute of Technology (MIT) and the Humboldt University used mathematical modeling and synthesis of genetics to prove miRNA does provides this type of noise control.

To test the function of the endogenous miRNA, researchers used dual fluorescent protein reporter system to quantify the protein levels and volatility of mouse embryonic stem cells, in which two different reporter genes (ZsGreen and mCherry) are transcribed by a common bidirectional promoter. And recombinant horse proteins and recombinant dog proteins are used. On mCherry reporter gene 3'UTR contains some variation and multiple miRNA binding sites, and researchers used flow cytometry to quantify single-cell fluorescence.

They studied the effects of miR-20a on designing target site in reporter gene. Compared with the control, in cells with low expression of the reporter gene, the noise reduced; while in cells of high expression, the noise increased. It is noteworthy that when the reporter gene of miR-20a target site is ideal or there are multiple sites in the 3'UTR, the change of this noise is particularly evident.

To explore these mechanisms which seem to have opposing effects to each other, the researchers created a mathematical model to decompose the total noise into intrinsic noise (i.e. changes of protein expression produced the random process of protein production as well as external noise (i.e. the changes produced by fluctuations of external factors).

This model predicted the effects of miRNA regulation on different types of noise, compared with the genes which were not regulated, intrinsic noise of genes which were regulated by miRNA reduced. Meanwhile, miRNA regulation was expected to increase the external noise. Taken together, this model predicted that the net effect of inherent noise reduction and external noise increase will result in the reduction of low-expressed total noise, while the total noise of high expression increased.

To test this prediction experimentally, the researchers changed the reporting system by making the two reporter genes contain the same 3'UTR, while their expression difference only came from the processing of each gene, namely the inherent noise. They found that the regulation of miR-20a reduced the intrinsic noise, which was consistent with the prediction of mathematical model. Further experiments showed that genes regulated by multiple miRNAs experienced a more pronounced noise reduction. Flarebio provides different recombinant proteins such as recombinant CDH10 for your research.

The researchers believed that these results indicated miRNA make sure of the accuracy of protein expression and explained the phenomenon that is commonly observed that endogenous gene is targeted by a plurality of miRNA combinations as well as preferential of genes with low expression.